FDA announces a new priority review program in bid to further administration goals

Taking stock of the drug industry, from the lab to the medicine chest

June 17, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Sarah Silbiger/Getty Images STAT+ | FDA announces a new priority review program in bid to further administration goals Recipients of a National Priority Voucher can expect decision in 1-2 months, down from 10-12, if a product aligns with FDA national health priorities. By Lizzy Lawrence STAT+ | Eli Lilly to buy gene-editing biotech Verve for up to $1.3 billion The deal gives the Indianapolis-based drug giant access to experimental cardiovascular treatments being developed by Verve. By Elaine Chen STAT+ | Isomorphic Labs sets up U.S. presence, with an eye on clinical trials Isomorphic Labs is setting up an office in Cambridge, Mass., as it prepares for clinical trials of some of its AI-enabled drug candidates. By Katie Palmer Courtesy Bill & Melinda Gates Foundation/Dan Lamont Opinion: Bill Gates: I lost my father to Alzheimer's. But I'm more optimistic than ever about fighting the disease "When we lost my dad, an Alzheimer's diagnosis was a death sentence. Just five years later, that is finally starting to change," writes Bill Gates. By Bill Gates

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser